Industry reports
Editor highlights

Search inside this page

All regions

Free Market Research Guides to Download

Pharmaceutical Analysis & Statistics in Germany, May 2013 (p8)

You might be interested in: therapeutics, cancer, drug, more »

» Purchase Premium Reports

211-260 of about 1 100 reports
EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022

EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • June 2013
  • by Global Data

EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2022 Summary Atopic dermatitis or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though ...

  • Industries : Pathology
  • Countries : India, China, Japan, World, Spain, Italy, France, Germany, United States, Europe, United Kingdom
Celsis International Ltd. SWOT Analysis, Strategy, Revenues and Profits

Celsis International Ltd. SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • June 2013
  • by Global Data

Celsis International Ltd. (Celsis) provides innovative life science products and laboratory services to pharmaceutical, biopharmaceutical, and consumer products industries. The company operates through ...

  • Industries : Drug Discovery and Development
  • Countries : United States, Netherlands, United Kingdom, France, Germany, Belgium
EpiCast Report: Type 2 Diabetes - Epidemiology Forecast To 2022

EpiCast Report: Type 2 Diabetes - Epidemiology Forecast To 2022

  • $ 3 995
  • Industry report
  • June 2013
  • by Global Data

EpiCast Report: Type 2 Diabetes - Epidemiology Forecast To 2022 Summary Type 2 diabetes, formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorde ...

  • Industries : Pathology
  • Countries : Japan, World, United States, India, China, Brazil, Spain, Italy, France, Germany, United Kingdom
EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022

  • $ 3 995
  • Industry report
  • June 2013
  • by Global Data

EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast To 2022 Summary Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths ...

  • Industries : Pathology
  • Countries : Spain, Italy, United States, World, France, Germany, Europe
Pharma Wholesale and Distribution Market: World Outlook 2013-2023

Pharma Wholesale and Distribution Market: World Outlook 2013-2023

  • $ 2 621
  • Industry report
  • June 2013
  • by Visiongain

Report Details Discover trends and revenue potential in distributing and wholesaling of medicines Where's the drug wholesaling and distribution market heading? Visiongain's updated report predicts revenues ...

  • Industries : Generic Drug
  • Countries : World, China, Europe, United States, Japan, India, Brazil, Russian Federation, France, United Kingdom, Spain, Italy, Germany, Asia
MarketVIEW: allergic immunotherapies

MarketVIEW: allergic immunotherapies

  • $ 8 995
  • Industry report
  • June 2013
  • by VacZine Analytics Group Of Assay Advantage Ltd

Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, house dust mite and cat dander. Prevalence in adults can range from 17 ...

  • Industries : Therapy
  • Countries : Japan, Europe, France, United States, Netherlands, Spain, Italy, Germany, World, United Kingdom, Denmark
PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, ?PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market ...

  • Industries : Drug and Medication
  • Countries : Germany
PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and ...

  • Industries : Drug and Medication
  • Countries : Germany
Enbrel (Psoriasis) - Forecast and Market Analysis to 2022

Enbrel (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Enbrel (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Enbrel (Psoriasis) - Forecast and Market Analysis to 2022?. There ...

  • Industries : Pathology
  • Countries : United States, Spain, Italy, France, Germany, China, World, Europe, United Kingdom
Humira (Psoriasis) - Forecast and Market Analysis to 2022

Humira (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Humira (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Humira (Psoriasis) - Forecast and Market Analysis to 2022?. There ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, Europe, United States, United Kingdom
Remicade (Psoriasis) - Forecast and Market Analysis to 2022

Remicade (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Remicade (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Remicade (Psoriasis) - Forecast and Market Analysis to 2022?. ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, Europe, United States, United Kingdom
Stelara (Psoriasis) - Forecast and Market Analysis to 2022

Stelara (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Stelara (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Stelara (Psoriasis) - Forecast and Market Analysis to 2022?. There ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, Europe, United States, United Kingdom
PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Psoriasis - Germany Drug Forecast and Market Analysis ...

  • Industries : Drug and Medication
  • Countries : Germany
Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Brodalumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Brazil, United States, Spain, Italy, France, Germany, Japan, Australia, Europe, United Kingdom, China
Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, Australia, Europe, United States, United Kingdom, China
Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, China
Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera ...

  • Industries : Pathology
  • Countries : Germany, Japan, World, Brazil, Spain, Italy, France, United States, Australia, Europe, United Kingdom, China
Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Brazil, United States, Spain, Italy, France, Germany, Japan, Australia, Europe, United Kingdom, China
Apremilast (Psoriasis) - Forecast and Market Analysis to 2022

Apremilast (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Apremilast (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide ...

  • Industries : Pathology
  • Countries : Italy, France, World, Brazil, Spain, Germany, Japan, United States, United Kingdom, Europe, Australia, China
Alzumab (Psoriasis) - Forecast and Market Analysis to 2022

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Alzumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide (Perera ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom, India, China
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, India, China, United States, Europe, United Kingdom
Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. ...

  • Industries : Pathology
  • Countries : Germany, World, Brazil, Spain, Italy, France, Japan, China, United States, Europe, United Kingdom
Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, India, China, United States, Europe, United Kingdom
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • May 2013
  • by Global Data

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute o ...

  • Industries : Pathology
  • Countries : World, Brazil, Spain, Italy, France, Germany, Japan, China, United States, Europe, United Kingdom
PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and ...

  • Industries : Pathology
  • Countries : Germany

» View Public Reports

About 400 reports

MediGene AG - Company Report for Year 2013

  • Company report
  • November 2013
  • 3 pages

... Partnership, syncore has undertaken to finance the phase iii trial in full. This trial is expected to start in the second half of 2014. Rhudex medigene plans to conduct a phase ii clinical trial in primary ...


» Read our Company Profiles

21 Companies

GlaxoSmithKline P.L.C.

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

Johnson and Johnson

United States

AstraZeneca PLC

United Kingdom

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.